Indian biotech startup claims breakthrough in early-stage cancer detection There is still significant work needed before it can translate into an accepted diagnostic test and a larger study needs to be completed at the earliest opportunity, an expert said.
Share Via Email
| A+A A- By Express News Service
BENGALURU: Tzar Labs, a molecular diagnostic company in coordination with the Mumbai-based Epigeneres Biotechnology, has claimed to have developed a breakthrough blood test for early prognosis/diagnosis of cancer.
The novel blood test, a first-of-its-kind globally, can help determine whether cancer is absent, imminent, or present, and also detect different stages of the disease, the company says.
Opinion: Digital maturity assessments - Lifting Germany onto the world stage healthcareitnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthcareitnews.com Daily Mail and Mail on Sunday newspapers.
Germany will soon be embarking on a national project to assess the digital maturity of its 2,000 hospitals. If it focuses on understanding the impact on clinicians and patients, it can catch up with the world’s digital health leaders, says Armin Scheuer, VP international business development, HIMSS.
A single dose of Pfizer and BioNtech's COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.
Kate Kelland
(Adds details, quotes)
LONDON, Feb 26 (Reuters) - A single dose of Pfizer and BioNtech’s COVID-19 vaccine cuts the number of asymptomatic infections and could significantly reduce the risk of transmission of the virus, results of a UK study found on Friday.
Researchers analysed results from thousands of COVID-19 tests carried out each week as part of hospital screenings of healthcare staff in Cambridge, eastern England.
“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.